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Background: This study describes the development of Response Surface Pathway (RSP) design, assesses its
performance and effectiveness in estimating LD50, and compares RSP with Up and Down Procedures (UDPs) and
Random Walk (RW) design.
Methods: A basic 4-level RSP design was used on 36 male ICR mice given intraperitoneal doses of Yessotoxin.
Simulations were performed to optimise the design. A k-adjustment factor was introduced to ensure coverage of
the dose window and calculate the dose steps. Instead of using equal numbers of mice on all levels, the number of
mice was increased at each design level. Additionally, the binomial outcome variable was changed to multinomial.
The performance of the RSP designs and a comparison of UDPs and RW were assessed by simulations. The
optimised 4-level RSP design was used on 24 female NMRI mice given Azaspiracid-1 intraperitoneally.
Results: The in vivo experiment with basic 4-level RSP design estimated the LD50 of Yessotoxin to be 463 μg/kgBW
(95% CI: 383–535). By inclusion of the k-adjustment factor with equal or increasing numbers of mice on increasing
dose levels, the estimate changed to 481 μg/kgBW (95% CI: 362–566) and 447 μg/kgBW (95% CI: 378–504 μg/
kgBW), respectively. The optimised 4-level RSP estimated the LD50 to be 473 μg/kgBW (95% CI: 442–517). A similar
increase in power was demonstrated using the optimised RSP design on real Azaspiracid-1 data. The simulations
showed that the inclusion of the k-adjustment factor, reduction in sample size by increasing the number of mice
on higher design levels and incorporation of a multinomial outcome gave estimates of the LD50 that were as good
as those with the basic RSP design. Furthermore, optimised RSP design performed on just three levels reduced the
number of animals from 36 to 15 without loss of information, when compared with the 4-level designs. Simulated
comparison of the RSP design with UDPs and RW design demonstrated the superiority of RSP.
Conclusion: Optimised RSP design reduces the number of animals needed. The design converges rapidly on the
area of interest and is at least as efficient as both the UDPs and RW design.
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In recent years, acute toxicity studies have been refined
to improve animal welfare. In particular, LD50 studies
are no longer the method of choice in toxicology studies
associated with pharmaceutical drug development, or
the development of food additives, flavourings, contact
materials and cosmetics [1]. In some areas, however, LD50
studies cannot yet be replaced by other methods. There is
an urgent need for alternative methods, both for ethical
reasons and because of the shortcomings of the bioassays,
in particular their sensitivity and specificity. In vitro
methods have been recommended by international ex-
pert groups [2]. However, before these can be adopted
information on the relative toxicities of all relevant ana-
logues in each toxin group must be obtained, in order
to establish toxic equivalency factors (TEFs) [3]. The
TEF approach was initially developed to estimate the
potential toxicity of mixtures of dioxins, dibenzofurans
and PCBs [4-6]. TEF studies of marine algal toxins are
based on LD50 studies in mice [3]. Ideally, these studies
should be performed by exposure via the oral route.
However, due to the scarcity of pure toxins in sufficient
quantities, LD50 studies are performed by intraperito-
neal (IP) injections in mice [7]. Until laboratory animal
studies can be replaced completely, it is of the utmost
importance to optimise trial design, in order to reduce
the number of animals used for this purpose [8].
The classical LD50 design introduced by Trevan in 1927
requires the use of a large number of animals [9]. The
design has been criticised for both ethical and scientific
reasons [10,11]. The Organization for Economic Co-
operation and Development (OECD) removed the clas-
sical LD50 (OECD 401) from their acute oral toxicity
guidelines in 2002 [12] and recommended OECD 425,
the Up and Down Procedure (UDP) to optimise LD50
design [13]. The UDP is a sequential procedure that
results in rapid convergence on the area of interest, the
dose for each animal being adjusted up or down de-
pending on the outcome for the previous animal. This
approach was established in 1948 [14] and Bruce pro-
posed the use of the UDP for determination of acute
toxicity to chemicals [15]. The UDP in the OECD guide-
lines uses a calculated dose progression factor based on
the antilog of 1 divided by the estimated slope of the
dose–response curve and should stay constant during
testing. Single animals are dosed until one of three criteria
to stop the trial is met [13].
The OECD’s UDP can only estimate the point of interest
and cannot be used to construct a dose–response curve
[9]. Furthermore, the single-animal strategy does not take
into account inherent biological variation, or the practical
problems that arise from having to test each mouse indi-
vidually. Tsutakawa introduced a block up and down
method known as Random Walk (RW) [16], where everysequence used more than one mouse. This design reduces
the number of trials and adds flexibility. The experiment
starts with n observations on a given level dj and con-
tinues with n observations, with the dose determined by a
procedure for generating the sequences.
In the field of engineering, the term Response Surface is
commonly used to obtain the optimal value for one re-
sponse variable. By combining the philosophy of UDP and
the principles of Response Surface methodology [17] the
basic Response Surface Pathway (RSP) design was created.
Basic RSP design is based on the theory of stochastic
chain models, where the procedure for generating the next
step is based on the response at the previous one. The
design consists of n levels in which the results obtained on
one design level determine the dose to be used on the
next. The starting dose used on the first design level is
designated m. This dose may be an educated guess made
by the responsible toxicologist. If a dose window for the
given toxin is known, the mid-dose of this window might
be a suitable choice. In order to estimate the LD50, an odd
number of laboratory animals is assigned to this starting
dose. If more than 50% of the animals die, the dose to be
used on the second design level is reduced by m/2. If not,
the dose is increased by the same amount (Figure 1). The
same number of animals is included on the second design
level. If 50% die, the second design level dose is reduced
by m/4 or conversely, if the animals survive, increased by
m/4 on the third design level. In general, the dose to be
used on design level i will be given by the equation:
mi ¼ mi−1  m
2i−1
wheremi−1 denotes the dose used
on design level i−1:
ð1Þ
This basic RSP-design has previously been used in tox-
icity studies to estimate LD50 with satisfactory results
[18,19]. However, these studies used a large amount of
animals and did not describe in detail the rationale behind
the dose steps. Using the data from one of these studies
[19], the concept of RSP has been refined and developed
using simulation procedures.
The aims of this paper were to introduce and describe
the optimisation of RSP design, to assess its performance
and effectiveness in estimation of LD50 and to compare
it with UDPs and RW design using simulations performed
on data from an in vivo experiment.
Methods
Material
The first in vivo study has been described in detail pre-
viously [19], and comprised 36 male ICR mice of SPF
quality (16-20 g) divided into 4 equal groups. The
study was conducted in 2006 and was authorized by the
Norwegian Animal Research Authority, in accordance
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Figure 1 The pathway obtained in the in vivo Yessotoxin study
using the basic 4-level RSP design. The basic 4-level RSP design
in in vivo Yessotoxin study used 9 mice on each design level with
the binomial outcome. The pathway obtained is indicated by
dashed line. The doses are given in μg/kg BW and the numbers
given in brackets are the ratios of dead mice.
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tation. The mice were given Yessotoxin (YTX) IP at
varying concentrations with a predefined LD50 dose
window of 100–700 μg/kg body weight (BW). The out-
come variable was “death” within the 24 hours after
injection.
Simulation study: All the simulation studies used the
LD50 of YTX derived from the material in the in-vivo
study to estimate the probability of death at a given
dose.
The second in vivo study consisted of 24 female NMRI
mice of SPF quality (15–21 g), randomly divided into 4
groups comprising 3, 5, 7 and 9 mice per cage, respect-
ively. The mice were supplied 1 week before the experi-
ment for acclimatisation purposes. They were housed on
aspen bedding in standard macrolone cages on a 12:12
light/dark cycle at 21-23°C with food and water available
ad libitum. The mice were nulliparous and were not
fasted before treatment. Injection volumes were adjusted
for bodyweight to 1 mL/20 g BW. The animals were ob-
served for 24 hours after injection. Symptoms and time
to death were recorded. The study was conducted in
2011 with the authorization of the Norwegian Animal
Research Authority, application number FOTS ID: 1132),
in accordance with the Norwegian Regulation on AnimalExperimentation. The mice were given Azaspiracid-1
(AZA1) IP in four different concentrations with a pre-
defined LD50 dose window of 25 - 375 μg/kg BW. The
outcome variable was the number of dead mice within
24 hours after injection.
Optimisation of the basic RSP design
Some prior information about the toxicity range is always
available, and can also be obtained by educated guesswork.
The study can then be focused on the area of interest,
thereby increasing the amount of useful information and
the efficiency of animal use. In basic RSP design, no atten-
tion is paid to upper or lower doses.
Let DU and DL denote the upper and the lower limits
of the dose window, respectively.
Let m denote the mid dose of the dose window, mi
the dose on design level i and k the dose adjustment
factor. The dose on the design level i is then given by
the equation
mi ¼ mi−1  m
ki−1
;mi−1denotes the dose used
on design level i−1
ð2Þ
Using the formula for the sum of a geometric series
[20,21], the upper dose DU of the window on the highest
design level n will be given by:
DU ¼ m k
n−1ð Þ
kn−kn−1
  ð3Þ
The dose window of the LD50 for YTX was from DL =
100 μg/kg BW to DU = 700 μg/kg BW. The middle dose of
the window was used as the starting dose, i.e. m = 400 μg/
kg BW. Using equation (3) above, the adjustment factor
k was:
700 ¼ 400 k
4−1
 
k4−k3
 →k ¼ 2:21
For AZA1, the predefined dose window of the LD50 was
from DL = 25 μg/kg BW to DU = 375 μg/kg BW which
gave a starting dose of 200 μg/kg BW. Using equation (3)
above this gives an adjustment factor k of:
375 ¼ 200 k
4−1
 
k4−k3
 →k ¼ 2:0
Increasing the number of animals with increased design
level
The basic RSP design uses an equal number of animals
on each design level. The starting dose is either based
on an educated guess or on the mid-dose of the dose
window. Due to the structure of the design, it is likely to
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sign level. It is therefore unnecessary to use the same
number of animals at the starting dose as on the highest
design level. By using the lowest possible number of
animals at the starting dose and increasing the number
at increasing design levels, the total number of animals
needed will be reduced without loss of information. One
practical solution is to use three animals on the first
level, five on the second, seven on the third, nine on the
fourth, and so on.
Multinomial outcome variable
In toxicological studies the most common outcome vari-
able is binomial. In the determination of the LD50, the
outcome is "dead" or "alive" after a certain time interval.
The decision to either increase or decrease the dose on
the next design level is based upon whether there were
more or less than 50% dead animals on the previous
level. However, there is clearly a difference between
outcomes where 0, 1, 2 or 3 animals die. It is reasonable
to assume that by changing the outcome variable from
binomial to multinomial, the amount of information
obtained will increase. The binomial outcome variable
can be replaced by "the number of dead animals". If
none of the animals die, the toxin dose can be increased
maximally on the next level. Conversely, if all the ani-
mals die on a given level, an equally large decrease in
the dose is performed (Table 1).
Comparisons of 3-level RSP design, UDPs and RW design
Simulation of all the four designs was performed on the
first in vivo material. The 3-level RSP with multinomial
outcome was performed with 3, 5, and 7 mice on design
levels 1, 2, and 3 respectively. The k-adjustment factor in
the 3-level situation was calculated to be 2. The UDP
simulation was performed using OECD 425 guidelinesTable 1 The doses assigned on the four design levels using th
Design level I
(3 animals)
Design level 2
(5 animals)
Outcome Dose (m2) Outcome Dose
0 m + m/k 0 m2 +
1 m + m/k2 1 m2 +
2 m - m/k2 2 m2 +
3 m - m/k 3 m2
4 m2
5 m2 -
The dose m =m1 is the starting dose. The number of mice used on the design leve[13]. The LD50 of YTX was assumed to be 400 μg/kg
BW with a sigma of 0.25 μg/kg BW and a progression
factor of 1.78. The same dose sequence and starting dose
for OECD’s UDP was used in both simple UDP and RW
design, which use 3 mice on each level. The dose was
decreased if more than 50% mice died, and increased if
less than 50% mice died. If no mice died in the RW
design, the dose was increased. If more than 2 mice died,
the dose was reduced. If one mouse died, a coin was
tossed to decide whether to increase the dose or stay at
the same dose. The starting dose was 225 μg/kg BW and
the simulations were halted when a total of 15 animals
had been included.
Simulation procedure
The YTX in vivo study was used to estimate the prob-
ability of death at a given dose using logistic regression
in a binomial distribution. A total of 10,000 simulated
mice samples were generated for each dose. The simula-
tion procedure was repeated 10 times and the average of
the 10 outcomes was used as the simulated result. The
same procedure was also carried out to compare 3-level
RSP Design, UDPs and RW Design. Three pathways
within the RSP design were considered to assess its per-
formance, with binomial outcome, k-adjustment factor
and either the same number of animals at each design
level or increasing numbers at increasing design levels,
respectively.
For the optimised 4-level RSP design with multinomial
outcome, k-adjustment factor and increasing numbers of
mice at increasing design levels, eighteen pathways were
created, but only four are of interest.
When assessing the performance of optimised 3-level
RSP design with multinomial outcome, k-adjustment fac-
tor and increasing number of mice with increasing design
level, eight pathways were created. As in the previouse k-adjustment factor and the dose mi at level i
Design level 3
(7 animals)
Design level 4
(9 animals)
(m3) Outcome Dose (m4) Outcome
m/k2 0 m3 + m/k
3 0
m/k3 1 m3 + m/k
4 1
m/k4 2 m3 + m/k
5 2
- m/k4 3 m3 + m/k
6 3
- m/k3 4 m3 - m/k
6 4
m/k2 5 m3 - m/k
5 5
6 m3 - m/k
4 6
7 m3 - m/k
3 7
8
9
ls was 3, 5, 7 and 9, respectively.
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was estimated using logistic regression in a binomial dis-
tribution from the YTX in vivo study. For each scenario,
the mean number of dead mice at the assigned dose in
10,000 simulations was recorded and the outcome was
used to simulate the number of dead mice at each design
level.
Statistical analysis
The results are expressed with 95% confidence inter-
vals (CIs) using isotonic regression [22] and trimmed
Spearman-Karber regression estimation [23]. The iso-
tonic regression was performed using the pooled
adjacent-violators algorithm (PAVA) [22]. The CIs were
obtained using parametric bootstrap numerical methods
[24]. The trimmed Spearman-Karber program originated
from Montana State University and was modified at
the Duluth and Athens National Exposure Research
Laboratories [25]. The LD50 in OECD’s UDP was ana-
lysed by Maximum Likelihood Estimation (MLE) using
AOT425 software [26].
Results
Basic RSP design (in vivo YTX study)
Three of the nine mice at the starting dose of 400 μg/kg
BW died and the dose for the second design level was
increased to 600 μg/kg BW (Figure 1). This resulted in
the death of five of nine mice, which resulted in a dose
of 500 μg/kg BW on the third design level. On this
design level, seven of nine mice died and the dose forTable 2 The estimated LD50 of Yessotoxin (YTX) in different d
Design Dose (μg/kg
Basic RSP 400
450
500
600
*) Included k-adjustment factor 400
462
499
581
*) Optimising use of mice 400
462
499
581
*) Multinomial decision variable with all four design levels 400
465
468
482
The results are expressed with 95% Confidence Intervals. *) Simulated data based othe fourth design was decreased to 450 μg/kg BW. Four
of nine mice died on the fourth and last design level.
Based on the data obtained, the LD50 of Yessotoxin was
estimated to be 463 μg/kg BW (Table 2).
The ways in which the pathways and results from a
single simulation study were used in each of the RSP
designs to estimate the LD50 are described below:
Application of the k-adjustment factor (simulated YTX
study)
The k-adjustment factor of 2.21 was calculated to ensure
that the design covered the total predefined dose window
(Figure 2). Of the nine simulated mice given 400 μg/kg
BW, three died and the dose for the second design level
was increased to 581 μg/kg BW. On this design level,
five mice died and the dose for the third design level
was decreased to 499 μg/kg BW. The simulated results
on this design level again resulted in five dead mice and
the dose for the fourth and last design level was set to
462 μg/kg BW. Four of the nine mice died. Based on these
simulated data, the LD50 was estimated to be 481 μg/kg
BW (Table 2).
Increasing number of mice with increasing design level
(simulated YTX study)
Of the three mice assigned to the first design level given
400 μg/kg BW, one died (Figure 2). The dose for the
second design level was increased to 581 μg/kg BW and
five mice were included. Four of these five died and the
dose for the next design level was reduced to 499 μg/kgevelopmental stages of RSP design
BW) Proportion of
dead mice
LD50 with 95% CI (μg/kg BW)
Isotonic regression Spearman-Karber
3/9 (0.33) 463 (383 – 535) 457 (400 – 522)
4/9 (0.44)
7/9 (0.78)
5/9 (0.56)
3/9 (0.33) 481 (362 – 566) 480 (408 – 565)
4/9 (0.44)
5/9 (0.56)
5/9 (0.56)
1/3 (0.33) 447 (378 – 504) 444 (379 – 521)
5/9 (0.56)
5/7 (0.71)
4/5 (0.80)
1/3 (0.33) 473 (442 – 517) 471 (430 – 516)
3/7 (0.43)
4/9 (0.44)
3/5 (0.60)
n the 36 observations in the basic RSP model.
m
400
m+m/k
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m+m/k+m/k2
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Figure 2 Simulated Yessotoxin studies using 4-level RSP designs
with k-adjustment factor with fixed and increasing number of
mice. The simulated Yessotoxin pathways obtained in the two 4-level
RSP designs. The pathways obtained are shown by dashed line. The
doses are given in μg/kg BW. The first design incorporates binomial
outcome, k-adjustment factor, and 9 mice at each design level, where
the ratios of dead mice are given in bracket. The second design
incorporates binomial outcome, k-adjustment factor and increasing
number of mice from 3 at the first level to 9 at the fourth, where
the ratios of dead mice are given in square brackets [ ].
400
581
663 700
680
671
666
659
655
646
626
618
598
564
544
499
482
564
519
499
465
502
482
473
468
462
457
448
428
445
400
318
400
355
334
301
281
236
219
301
256
236
202
182
137
174
153
145
140
133
129
120
100
1/3
3/5 3/7
4/9
Design
Level 1
Design
Level 2
Design
Level 3
Design
Level 4
Figure 3 The obtained pathway in the simulated Yessotoxin
study using the optimised 4-level RSP design. The optimised
4-level RSP design incorporates multinomial outcome, used
k-adjustment factor and increasing number of mice with increasing
design levels, and the pathway obtained in the simulation study is
shown by dashed line. The doses are given in μg/kg BW and the
numbers in the callouts represent the ratios of dead mice.
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which led to a reduction to 462 μg/kg BW for the fourth
design level. Nine mice were simulated on this level and
5 died. Based on these simulated data, the LD50 was
estimated to be 447 μg/kg BW (Table 2).
Number of dead mice as outcome or decision variable
(simulated YTX study)
Three mice were assigned in the simulation to 400 μg/kg
BW on the first design level and one died (Figure 3).
The dose for the second design level was increased to
482 μg/kg BW and three of the five mice died. Conse-
quently, the dose was decreased to 465 μg/kg BW and
three of the seven mice died. The dose for the fourth
design level was increased to 468 μg/kg BW and four of
nine mice died. Based on the simulated data, the LD50
was estimated to be 473 μg/kg BW (Table 2).
Performance of the RSP designs
The estimated LD50 of YTX with a 95% confidence inter-
val obtained in vitro was used as the reference in evalu-
ation of the simulated results of the three RSP designs.
For pathway 01 (Table 3), 24 and 10 scenarios, respect-
ively were created for the 4-level RSP designs withbinomial outcome, k-adjustment factor and nine mice on
each design level or with increasing number of mice from
three on the first level to nine on the fourth. For both of
these two RSP designs, all the estimated LD50 deviated
with a maximum of 10% from the in vitro reference.
The estimated LD50 from pathway 02 was higher than
the reference value. For the RSP design with binomial
outcome, k-adjustment factor and nine mice at each
level, three of the 12 scenarios deviated with a max-
imum of 10% from the in vitro reference. By increasing
the number of mice from three on the first design level
to nine on the fourth, two of six scenarios fulfilled the
same demands. All the scenarios in pathway 03 esti-
mated the LD50 to be below the in vitro reference
value. Simulation of the optimised 4-level RSP design
with multinomial outcome, k-adjustment factor and
increasing numbers of mice from three to nine on the
last level, estimated the LD50 in 11 of 18 pathways with
a deviation of at most 10% from the in vitro reference
(Figure 4).
Table 3 Mean values of estimated LD50 of Yessotoxin in different pathways using 4-level RSP designs
Pathway Dose on design
level 1
Dose on design
level 2
Dose on design
level 3
Dose on design
level 4
Mean LD50 (μg/kgBW) 95% CI of Mean
LD50 (μg/kgBW)
4-Level RSP design with binomial outcome, k-adjustment factor and 9 animals at each design level
01 400
M = 3.29
581
M = 6.23
499
M = 5.01
462
M = 4.38
457 449 – 466
02 400
M = 3.29
581
M = 6.23
499
M = 5.01
536
M = 5.07
513 510 – 516
03 400
M = 3.29
219
M = 0
301
M = 1.05
338
M = 1.97
391 389 – 392
4-Level RSP design with binomial outcome, k-adjustment factor and increasing number of mice with increasing design levels
01 400
M = 1.10
581
M = 3.35
499
M = 3.9
462
M = 4.41
464 449 – 479
02 400
M = 1.10
581
M = 3.35
499
M = 3.9
536
M = 5.57
510 501 – 520
03 400
M = 1.10
219
M = 0
301
M = 0.82
338
M = 1.96
379 374 – 384
4-Level RSP design with multinomial outcome, k-adjustment factor and increasing number of mice with increasing design levels
01 400
M = 1.10
482
M = 2.45
499
M = 3.87
502
M = 5.06
501 498 – 503
02 400
M = 1.10
482
M = 2.45
499
M = 3.87
496
M = 4.97
490 470 – 510
03 400
M = 1.10
482
M = 2.45
465
M = 3.48
468
M = 4.51
470 432 – 508
04 400
M = 1.10
482
M = 2.45
465
M = 3.48
462
M = 4.41
455 353 – 557
The results are expressed with 95% Confidence interval. M represents the mean of dead mice based on 10,000 simulations on the assigned dose.
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sign resulted in similar estimation of LD50 (Figure 4). A
total of eight pathways were formed with the optimised
3-level RSP design and the estimated LD50 deviated with
a maximum of 10% from the in vitro reference in 50% of
the cases.Application of the complete RSP design (in vivo AZA1
study)
Three mice were given the starting dose of 200 μg/kg
BW and all died within 24 hours (Figure 5). In accordance
with the design, the dose for the second design level was
decreased to 100 μg/kg BW, but all five mice died. The
dose for the third design level was decreased to 50 μg/kg
and all seven mice survived 24 hours after the injection.
By only including data up to the third level, the LD50 of
AZA-1 was estimated to be 76.3 μg/kg BW and 70.7 μg/kg
BW using isotonic regression and the Spearman-Karber
method, respectively. For the fourth design level, the dose
was increased to 75 μg/kg BW, where four of the nine
mice died. Inclusion of all four design levels resulted in
estimation of the LD50 of AZA1 to be 77.5 μg/kg BW
(95% CI: 68 – 88 μg/kg BW) using isotonic regression and
74 μg/kg BW (95% confidence interval: 66 – 83 μg/kg
BW) using the Spearman-Karber method.Comparisons of 3-level RSP, UDPs and RW design
In the 3-level RSP design, three mice were given a starting
dose of 400 μg/kg BW (Table 4). One of the three mice
died and 500 μg/kg BW was then given to 5 mice. Three
of the 5 mice died and the 7 mice on the third design level
were given 475 μg/kg BW. Four of the seven mice died
and the LD50 of YTX was estimated to be 453 μg/kg BW.
The length of the CI was 133 μg/kg BW.
The simulation of OECD’s UDP was started by including
one mouse given a dose of 225 μg/kg BW. The mouse sur-
vived. The next mouse was assigned to 400 μg/kg BW and
survived. The third mouse died at 710 μg/kg BW and the
dose was then decreased again to 400 μg/kg BW. The
fourth mouse survived this dose and the fifth mouse was
given a dose of 710 μg/kg BW. The fifth mouse died and
the dose for the next mouse was decreased again to
400 μg/kg BW. This sixth mouse survived. The study was
stopped after six mice since one criterion for this had been
met and the LD50 was estimated to be 400 μg/kg BW
(Table 4). The length of the CI was 779 μg/kg BW.
In the simple UDP, none of three mice given a start-
ing dose 225 μg/kg BW died. In the second simulation
sequence a dose of 400 μg/kg BW was given and 2 of 3
mice died. The dose was decreased to 225 μg/kg BW
and all the mice survived. Consequently, a dose of
400 μg/kg BW was again assigned and one of 3 mice
OPTIMISED 4-LEVEL RSP OPTIMISED 3-LEVEL RSP
LD
50
 
( µ
g/k
g B
W
)
Figure 4 The estimation of LD50 using the optimised 3- and 4-level RSP designs. The optimised 3-level and 4-level RSP designs incorporate
multinomial outcome, using k-adjustment factor and increasing number of mice with increasing design levels. The numbers of pathways are given
along the x-axis, where the orange dots represent estimated value for 4-level RSP design and blue dots estimated value for 3-level RSP design.
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and 2 of 3 mice died.
In the RW design, three mice were given a dose of
225 μg/kg BW and all survived. In the next sequence,
three mice were allocated a dose of 400 μg/kg BW and
two mice died. The dose was decreased again, and three
mice survived at 225 μg/kg BW. The dose was again
increased to 400 μg/kg BW and one of 3 mice died. A
coin was tossed to decide whether to increase or stay at
the same dose: the dose was increased to 710 μg/kg BW
and 2 of 3 mice died. The LD50 of YTX was estimated to
be 400 μg/kg BW both in the simple UDP and RW design
(Table 4), and the length of the CI was 514.8 μg/kg BW.
Comparison of the four designs showed that OECD’s
UDP, simple UDP, and RW design resulted in CIs that
were 4.9, 2.9, and 2.9 times larger, respectively, than the
RSP design.
Discussion
When designing a classical LD50 study, the dose window
is divided into fixed dose intervals of equal range that
cover the dose window. In the present example with a
dose window of 100–700 μg/kg BW, the classical LD50
study with four dose levels would entail the same number
of animals being assigned to doses of 100, 300, 500, and
700 μg/kg BW, respectively. A comparison of the classical
LD50 design and RSP design demonstrates the strength of
RSP. Only one of the doses chosen for a classical LD50
study is close to the real LD50. In the present study wherethe LD50 was estimated from the basic RSP design and the
four simulated studies using optimised RSP design, the
dose assignments ranged from 400 to 581 μg/kg BW.
The lowest dose assigned, which was in the simulation
of 4-level RSP design with k-adjustment factor, a fixed
number of mice on each design level or increasing num-
bers with increasing design level, was 218 μg/kg BW.
However the probability for assigning this dose in real life
is minimal. Assigning doses based on the number of dead
animals, as was done in the optimised RSP design, gave an
opportunity to allocate a more appropriate dose.
To our knowledge, no rational procedure for choosing
the size of the increase or decrease in dose has been
described for UDP and the change in dose is the same
regardless of the dose level. OECD recommends that the
dose adjustment or progression factor in UDP design is
based on the estimated slope of the dose–response curve
and should remain constant throughout the test. If no
information about this slope is available, a constant ad-
justment factor of 3.2 should be used [13]. In the basic
RSP design an attempt is made to solve this problem by
using a fixed but chosen dose adjustment factor of 2.
Moreover, the size of the increase and decrease in dose
depends on the design level. Toxicologists have quite
often a predefined dose window for the toxin to be
investigated. By using a chosen dose adjustment factor
or predefined incremental procedure, doses outside the
dose window are less likely to be included. This may re-
duce the amount of information in the basic RSP design
200
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Figure 5 The obtained pathway in the in-vivo Azaspiracid-1 study
using the optimised 4-level RSP design. The optimised 4-level RSP
design incorporates multinomial outcome, using k-adjustment factor
and increasing number of mice with increasing design levels, the
pathway obtained is shown by dashed line. The doses are given in
μg/kg BW and the numbers in the callouts represent the ratios of
dead mice.
Table 4 Comparisons of optimised 3-level RSP Design,
UDPs and Random Walk Design in estimation of LD50
of YTX
Design Dose
(μg/kg BW)
Proportion of
dead mice
LD50 with
95% CI
(μg/kg BW)
Multinomial outcome
variable with 3-level
RSP design
400 1/3 453 (380 – 513)
475 4/7
500 3/5
UDP of OECD 225 0/1 400 (198 – 977)
400 0/3
710 2/2
Simple UDP 225 0/6 400 (65.2 – 580)
400 3/6
710 2/3
Random walk design 225 0/6 400 (65.2 – 580)
400 3/6
710 2/3
The results are expressed with 95% Confidence Intervals.
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the basic RSP design, the fixed dose adjustment factor of
2 has therefore been amended in our study to an adjust-
ment factor k dependent upon the predefined dose win-
dow. This factor is related to the number of levels in the
design and is calculated by a simple procedure to ensure
that all the values in the dose window will be covered.
Intuitively, this will increase the power of the design,
even though this was not clearly demonstrated by the
results of the simulations in the present study.
The choice of the middle of the dose window as a
starting point is based on an assumption that this dose
is more likely to be the LD50. Using the mid-dose and the
procedure for calculation of the k-adjustment ensures both
the upper limit (DU) and the lower limit (DL) of the dose
window will be covered. The predefined dose window forAZA toxin was 25–375 μg/kg BW. No information was
available on where in the window the value of LD50 was
likely to be. The LD50 was assumed to be 200 μg/kg BW.
However, the true LD50 turned out to be close to the lower
part of the dose window. The design made a pathway
directly to the area of interest after inclusion of only 3
animals.
The number of animals used in these studies was quite
small. Maximum Likelihood Estimation (MLE) does not
seem to be suitable in design analysis when the sample
size is small [27]. The Trimmed Spearman-Karber method
[23], which was used in the present study, requires at least
one mortality rate that is less than or equal to 50% and at
least one that is greater or equal to 50%. This method is
recommended because it is freely available and it is a sim-
ple program for those who are not highly skilled in statis-
tical analysis. Non-parametric modified isotonic regression
may be a more optimal method and is recommended for
small samples [22]. It is slightly more complicated, but can
easily be calculated manually. Furthermore, this method
assumes that the chance of toxicity does not decrease
over the set of possible dosages. The analysis of the
present data gave similar results with these two statis-
tical methods.
A reduction in the number of laboratory animals is a
central aim of UDPs, RW and RSP design. The UDP
[15] actually recommends that only one animal is used
on each dose level. The single-animal strategy used in
OECD’s UDP might at first sight appear advantageous in
reducing the number of animals in the study, but it does
not take into account the inherent biological variation in
an animal model. The probability of changing the dose
on the next level in the wrong direction is high and may
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lem by including more than one animal on each level.
As in the simple UDP and RW design, basic RSP-design
uses more than one animal, with equal numbers on each
dose level. Due to the structure of the design, the dose
always converges on the end result with increasing dose
level. It seems therefore apparent that it is unnecessary
to use the same number of animals at the starting dose
as on the last dose level. By using the lowest possible
number of animals at the starting dose and increasing
the number of animals on increasing dose levels, the
total number of animals will be reduced. In order to
avoid the problem of biological variation that is not
addressed in OECD’s UDP, the procedure should be to
start with 3 animals at the first dose level and continue
with 5, 7 and 9 animals, respectively, on subsequent
levels. This reduces the total number of animals from 36
to 24. The present simulation indicated that the ability
of the modified RSP designs to estimate LD50 values was
equally good as the basic RSP design.
A large disadvantage of most of the designs that have
been proposed for this area is the binomial outcome
variable. So far, this has also been the case for the basic
RSP design. However, the decision variable can easily be
changed from "more or less than 50% dead mice" to “the
number of dead mice”. If none or only one of the three
mice on the first design level dies, the dose for the next
design level has to be increased, otherwise it is decreased.
A similar procedure is used on the next design level. The
simulation of this procedure in the present paper clearly
demonstrated a substantial increase in the power of the
RSP design. From the simulated results it seems that the
increase in information in the model is so large that the
fourth level of the design can be omitted. The number of
animals can therefore be reduced from the initial 36 in the
basic RSP design to 24 by including the k-adjustment dose
factor and by increasing the number of animals at increas-
ing design levels. The simulation results also indicated that
the optimised 3-level RSP design estimated the LD50 as
well as all the other 4-level RSP variants. By reducing the
number of levels in the design from 4 to 3, only 15 ani-
mals are needed. The optimised RSP design created more
pathways, estimated LD50 slightly higher and performed
better than the other two RSP designs.
The RSP design should be performed sequentially and
the dose to be used on the next design level is not avail-
able until the experiment on the previous level has ended.
This may result increase the duration of the study as a
whole. Furthermore, experimental conditions such as the
weight of the animals, the composition of the test com-
pound, variations in the time to death and environmental
factors may differ between design levels and influence the
results. A reduction from four to three design levels is
therefore an advantage for many reasons.The complete optimised RSP design was used in the
AZA1 toxicity study. In this experiment, the predefined
dose window of AZA1 was quite large and the dose used
on the first design level proved to be far from the end
result. The study demonstrated the power of the design
and that the area of interest was already detected by the
third design level. This underlines the fact that the
fourth design level of the 9 mice was not needed and 15
mice would have been sufficient. If the AZA1 study had
been performed using optimised 3-level RSP design, the
k-adjustment factor would have been 1.78 and the esti-
mated LD50 would not have been different from the
value estimated by using the optimised 4-level RSP
design. In order to simulate an optimal 3-level RSP for
estimation of the LD50 of AZA1, the results obtained in
the prospective 4-level study were used. All the three
mice at the first design level died, which led to a dose of
88 μg/kg being assigned on the second level, where 3 of
5 mice died. The dose for the third design level was then
reduced to 68 μg/kg and 3 of 7 mice died. This simulation
estimated the LD50 of AZA1 to be 76.3 (95% CI: 38.5 -
101.58) and 75.7 μg/kg BW (95% CI 49.4 – 116.2) using
isotonic regression and the Spearman-Karber method,
respectively. The confidence intervals were, as expected,
larger compared to those in the prospective 4-level RSP
design study, but they still support the use of only 3 dose
levels.
The simulated comparison between 3-level RSP, UDPs
and RW design showed that the RSP reduced the number
of study sequences compared to the other two designs.
One way of comparing the information from the three de-
signs is to compare the length of the CI for the parameter
in question. If this is done, the RSP design was clearly su-
perior to both the RW and the UDPs. Both the simulation
and the results from the AZA1 study showed that the RSP
designs rapidly converge on the area of interest. The RSP
design was found to increase the information that
could be obtained and it was possible to develop a
dose–response curve.
The optimized 3-level RSP-design has recently been
used in two other studies (manuscripts in preparation).
However, further studies are needed to confirm the per-
formance of the 3-level RSP design.
The dose to be used on a given design level in the RSP
design is derived mathematically and may in some cases
be impossible to titrate or administer in the laboratory.
In these cases the dose must be adjusted to the nearest
practicable value.
The determination of LD50 in the present paper was
merely used to demonstrate how the RSP design was
optimised. The designs can also be used to estimate the
LDX, where 50% is replaced by x%. This design can also
be used in other areas of medicine. The most relevant of
these may be dose-finding studies, but the RSP design is
Dewi et al. BMC Pharmacology and Toxicology 2014, 15:18 Page 11 of 11
http://www.biomedcentral.com/2050-6511/15/18also applicable to studies where the primary aim is estima-
tion of quantile response.
Conclusions
The RSP is a sequential design, which can reduce the
number of animals needed to a minimum without loss of
information. The design takes into account the variation
in response between animals, using prior knowledge and
information obtained during the study and it converges
rapidly on the area of interest. It is as least as efficient as
both the UDPs and RW designs.
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